Company Filing History:
Years Active: 2023-2025
Title: Ralf Dieter Hoffmann: Innovator in Pre-Surgical Risk Stratification
Introduction
Ralf Dieter Hoffmann is a notable inventor based in Eindhoven, Netherlands. He has made significant contributions to the field of medical technology, particularly in the area of pre-surgical risk assessment for prostate cancer patients. With a total of 2 patents, Hoffmann's work aims to enhance treatment decisions and improve patient outcomes.
Latest Patents
Hoffmann's latest patents include a method for pre-surgical risk stratification based on the expression of specific genes. This invention involves determining a gene expression profile for phosphodiesterase 4D variant 7 (PDE4D7) and DExH-box helicase 9 (DHX9) in biological samples from prostate cancer subjects. By calculating a pre-surgical prognostic risk score, this method allows for better treatment recommendations, such as choosing between active surveillance and radical prostatectomy.
Another significant patent is a subject clustering method and apparatus. This method groups similar subjects based on quantitative clinical or pathological features. It employs principal component analysis (PCA) to generate weighting values that modify the dataset, followed by a clustering algorithm to identify groups of similar subjects. This iterative process continues until specific stopping conditions are met.
Career Highlights
Throughout his career, Hoffmann has worked with prominent organizations, including Koninklijke Philips Corporation N.V. and the University of Glasgow. His experience in these institutions has contributed to his expertise in medical innovations and research.
Collaborations
Hoffmann has collaborated with notable professionals in his field, including George Baillie and Sergio Consoli. These partnerships have likely enriched his research and development efforts.
Conclusion
Ralf Dieter Hoffmann is a distinguished inventor whose work in pre-surgical risk stratification and subject clustering has the potential to significantly impact prostate cancer treatment. His innovative approaches and collaborations continue to advance the field of medical technology.